Madeline Streifer, Ph.D.

Project Scientist

Madeline Streifer, Ph.D. Project Scientist

Dr. Madeline Streifer is a pharmacologist and toxicologist with experience in neuroendocrinology and reproductive health. She has led several multidisciplinary research projects investigating the impacts of endocrine-disrupting chemicals with a focus on dose-response assessment and exposure evaluation to assess chemical risks. Dr. Streifer is skilled in translating complex scientific data into actionable insights and has published several papers and presented her work at national conferences, contributing to the advancement of toxicology and environmental health research.

Ph.D., Pharmacology and Toxicology, University of Texas at Austin, Austin, Texas, 2024

B.S., Molecular, Cell, and Developmental Biology, University of California at Santa Cruz, Santa Cruz, California, 2016

Clinical Trials Design and Management (2019), University of California, San Diego, Extended Studies

Member of Endocrine Society

Member of Women in Endocrinology

Pharmacy Graduate Student Endowment (University of Texas at Austin, 2023)

University of Texas Pharmacy Dean’s Fellowship (University of Texas at Austin, 2019–2023)

University of Texas Provost Recruitment Fellowship (University of Texas at Austin, 2019)

Madeline Streifer, Ph.D.

Project Scientist

Toxicology

Toxicology

Effects of Endocrine-Disrupting Chemicals on Neuroendocrine Function, Austin, Texas Designed and led research projects investigating the toxicological impact of endocrine-disrupting chemicals on brain development and reproductive health in a rodent model. Assessed toxicity of both mixtures and individual compounds at environmentally relevant doses. Completed statistical analysis and interpreted data to assess exposure effects.

High-Throughput Screen for Compounds That Modulate Neurite Growth of Human Induced Pluripotent Stem Cell (hiPSC)-Derived Neurons, San Diego, California Assisted in the development of technology platforms to perform compound screens of hiPSC-derived neurons with relatively high throughput. Sampled 4,421 bioactive small molecules, identifying 108 hit compounds, including 37 approved drugs, that target molecules or pathways known to regulate neurite growth.

RETURN TO OUR TEAM PAGE